Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Canopy Growth

Curaleaf Holdings, Inc.

AdvisorShares Pure US Cannabis ETF

Trulieve Cannabis Corp.

Cannabis stocks moved sharply higher in late afternoon trading on Thursday after Republican presidential nominee Donald Trump said he's shifting his position in favor of looser cannabis laws.

Cannabis stocks post sharp gains as Trump says he's starting to ‘agree more' about reforms

ST. LOUIS, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Shock Top, a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and 'the king of zest', is pleased to announce the return of its highly anticipated seasonal brew, Shock Top Twisted Pretzel. After a three-year hiatus, the unique seasonal brew is back and here to shake up autumn, with a twist of flavor!

Move Over Pumpkin Spice, Shock Top Reclaims Autumn With the Return of Twisted Pretzel

Celebrate with live music, local vendors, raffles and prizes at Breckenridge Brewery's First Pour Party Celebrate with live music, local vendors, raffles and prizes at Breckenridge Brewery's First Pour Party

Breckenridge Brewery Opens New Location in Fort Collins, Colorado

Aurora Cannabis

Scotts Miracle-Gro

SNDL Inc.

Make no mistake: it's still a time when you should be thinking about which cannabis stocks to sell, not which cannabis stocks to buy. Yes, based on the sheer volume of public comments submitted to the Drug Enforcement Administration ( DEA ) in support of a proposed rescheduling of marijuana, U.S. cannabis legalization progress seemingly keeps moving in the right direction.

7 Struggling Cannabis Stocks to Sell by 2025

Cronos Group

Cannabis stocks have been through an extended period of depression. Overcapacity, regulatory headwinds, competition, and cash burn have contributed to the decline in the cannabis industry.

What Are the Hottest Cannabis Stocks Right Now? 3 Top Picks.

Marijuana stock investors are prepping for future trading. Many who are invested in cannabis are focused on the long term. With how volatile the sector can be there have been some moments to take profits. However, with the need for better regulations and all-around reform planning for the future is where many feel the money is. Currently, there is no federal reform in place even with the DEA's approval to reschedule cannabis.

3 Marijuana Stocks For Investors To Trade Today

Tilray's craft beer acquisitions are driving sales higher. Management expects continued revenue growth in fiscal 2025.

Why Tilray Stock Jumped Today

TLRY stock soared Tuesday and has reclaimed its 50-day moving average. Is now the time to buy the cannabis stock?

Is Tilray A Buy As Cannabis Stock Gets Higher Following Earnings?

Almost a year ago to the day, Tilray Brands Inc. made a big bet on craft beer, buying a clutch of brands from Anheuser-Busch, including the popular Shock Top, Montauk Brewery and Redhook Brewery.

Cannabis company Tilray made a huge bet on craft beer. It's already paying off.

Tilray reported strong revenue growth in FQ4, but most of it was not organic, mainly driven by acquisitions in the Beverage Alcohol sector. Despite acquisitions, non-beverage segments saw a decline in non-wholesale sales, raising concerns about the company's ability to manage a far-flung business effectively. The company forecast limited organic growth for Tilray in FY25, making TLRY stock expensive trading at 17x adjusted EBITDA and a history of missing financial targets.

Tilray: Never Great Under The Surface

Canadian cannabis and beverage firm Tilray beat top and bottom street estimates for its fiscal Q4 period. The company has made strong progress on reducing its large debt pile. While progress is being made, shareholders are facing significant dilution over time.

Tilray Shows Some Nice Improvement In Q4

Tilray Brands, Inc. (NASDAQ:TLRY ) Q4 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Robert Moskow - TD Cowen Andrew Carter - Stifel Aaron Grey - Alliance Global Partners Owen Bennett - Jefferies Frederico Gomes - ATB Capital Markets Conference Call Participants Berrin Noorata - Chief Corporate Affairs and Communications Officer Irwin Simon - Chairman and CEO Carl Merton - CFO Denise Faltischek - Chief Strategy Officer and Head of International Operator Hello, and thank you for joining today's conference call to discuss Tilray Brands' Financial Results for the Fourth Quarter and Fiscal Year 2024 ended May 31, 2024. [Operator Instructions] I'll now turn the call over to Ms.

Tilray Brands, Inc. (TLRY) Q4 2024 Earnings Call Transcript

The headline numbers for Tilray Brands (TLRY) give insight into how the company performed in the quarter ended May 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Tilray Brands (TLRY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.

Tilray Brands, Inc. (TLRY) Reports Q4 Loss, Tops Revenue Estimates

Record Fiscal 2024 Gross Profit Reduced Net Convertible Debt by ~$300 Million in Fiscal 2024 Fiscal 2024 Net Revenue Reaches $789 Million, Led by Cannabis Net Revenue of $273 Million and Beverage-Alcohol Net Revenue of $202 Million Successfully Executing on Diversified Lifestyle Business Strategy; Tilray Cannabis, Tilray Beverages, Tilray Spirits and Tilray Wellness NEW YORK and LEAMINGTON, Ontario, and NEÜMUNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle consumer packaged goods company elevating lives through moments of connection, today reported financial results for its fourth quarter and fiscal year ended May 31, 2024. Irwin D. Simon, Chairman and Chief Executive Officer, stated, “Tilray Brands is leading the convergence of cannabis, beverages, and wellness on a global scale.

Tilray Brands Reports Record Financial Results, Achieves 26% Net Revenue Growth

Tilray (NASDAQ: TLRY ) stock is on the move Monday as investors in the cannabis company react to it securing a trading license in Germany for its Aphria RX subsidiary. With this trading license, Aphria RX is now able to sell and distribute medical cannabis products to a wide range of locations.

TLRY Stock: Tilray's Aphria RX Receives Cannabis Trading License in Germany

NEUMÜNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in medical cannabis research, cultivation, production, and distribution, today announced that Aphria RX GmbH (“Aphria RX”) has received a trading license, which will allow it to sell and distribute a broad range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany.

Tilray's Aphria RX Receives Cannabis Trading License in Germany, Significantly Expanding Commercial Growth Opportunities

Tilray Brands (NASDAQ: TLRY) stock price will be in the spotlight this week as it publishes its second-quarter financial results. These numbers will come at a time when it is hovering near its year-to-date low of $1.60.

Tilray Brands (TLRY) stock price has bottomed: July 29 will be key

Tilray's (TLRY) product innovation, spanning medical cannabis formats, THC-infused beverages and pharmaceutical-grade medicines, enhances its ability to capture new market segments globally.

Tilray Brands (TLRY) Lined Up for Q4 Earnings: What Awaits?

Tilray Medical receives second approval for new medical cannabis extract in Portugal: Tilray Oral Solution THC10:CBD10 or Tilray Solução Oral THC10:CBD10.

Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal

Tilray Brands, Inc. (TLRY) closed at $1.89 in the latest trading session, marking a -1.56% move from the prior day.

Tilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key Insights

Cannabis stocks have gained in the past couple of months following the federal government's reclassification of the drug. Experts also anticipate that the lobby to lift the ban on the U.S. financial institutions financing cannabis stocks and the reclassification may see the industry market value double to $57 billion by 2028.

Get Your Money Out of These 3 Cannabis Stocks by 2025

Tilray Brands (NASDAQ: TLRY ) stock jumped almost 3% early on July 22 after it got good news from Germany. The marijuana and beer company received a cultivation license from German authorities.

Tilray Stock Pops as Germany Grants It a Cultivation Green Light

Tilray Brands Inc (NASDAQ: TLRY) has made a significant stride in its European operations by securing a new cannabis cultivation license in Germany.  This development, under the country's new Cannabis Act (MedCanG), is set to substantially boost the production capacity of Tilray's Aphria RX GmbH facility in Berlin.

Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY?

Tilray's Aphria RX Facility in Germany Granted New Cannabis Cultivation License, Allowing for ~5x Production Increase and New Strains to Enhance Patient Access Across the Country Aphria RX Designed with Guidance from Renowned Cannabis Grower of Broken Coast Cannabis NEUMÜNSTER, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that its Germany cannabis cultivation facility, Aphria RX GmbH (“Aphria RX”), has received the first new cannabis cultivation license issued under MedCanG, Germany's new Cannabis Act. The new cannabis cultivation license allows Aphria RX to cultivate and manufacture a broad commercial range of medical cannabis, providing patients with better access to high-quality medical cannabis produced in Germany.

News for Tilray Brands Stock (TLRY)